Actively Recruiting
Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-03-20
45
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research explores how HIV-1 and SARS-CoV-2 viruses may infect long-lived hematopoietic stem and progenitor cells (HSPCs) that have the ability to renew themselves. These infected cells could become a lasting source of infected cells, affecting the process of blood cell formation known as hematopoiesis. The study aims to understand virus-induced immunosuppression, a condition where immune cells decline due to viral infections, which is serious and seen in chronic HIV-1 and some COVID-19 patients. The mechanisms behind this immunosuppression and effective treatments are not well known. The study will evaluate which types of HSPCs are targeted by HIV-1 and SARS-CoV-2, both inside the body and in laboratory settings. It will also assess whether infected HSPCs change the bone marrow environment by increasing inflammatory signals that could harm the production of lymphocytes, a type of immune cell. This observational study does not involve treatments but focuses on detailed evaluations. Participants include HIV-positive patients with various viral loads and healthy individuals who have had bone marrow biopsies or myelograms as part of their medical care at Ambroise Paré Hospital. Researchers will monitor the bone marrow environment over a year to see how infected cells may affect it. Various tests and analyses will be performed to measure immune status and bone marrow changes throughout the study until its completion in March 2026.
CONDITIONS
Brief Title
Viral Infection of HSPC Impacts Hematopoiesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HIV-positive patients with either negative or positive viral load
- Managed at Ambroise Paré Hospital
- Patients with a bone marrow biopsy or myelogram performed as part of their care
- Healthy subjects without HIV who have had a bone marrow biopsy or myelogram for suspected hematological issues
- Managed at Ambroise Paré Hospital
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants provide bone marrow biopsies or myelograms as part of their routine care for evaluation of hematopoietic stem and progenitor cells (HSPC) infection.
1 to 2 visits depending on clinical care
Duration - Up to 1 year
Participants are monitored for changes in the bone marrow environment and immune cell function over time.
Trial Site Locations
Total: 1 location
1
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, France, 92100
Actively Recruiting
Research Team
C
Claude CAPRON, MD, PhD
F
Fernando REAL, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here